Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment

Neuro-Oncology

Volumn 12, Issue 4, 2010, Pages 377-388

  Pellegatta, Serena ^a   Poliani, Pietro Luigi ^b   Stucchi, Elena ^a   Corno, Daniela ^a   Colombo, Chiara Agnese ^a   Orzan, Francesca ^a   Ravanini, Maria ^b   Finocchiaro, Gaetano ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Dendritic cells; Glioma; Intratumoral vaccination; Tumor microenvironment

Indexed keywords

B7 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CELL SURFACE MARKER; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; SUPERPARAMAGNETIC IRON OXIDE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL LABELING; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN; CELL STRAIN GL 261; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; TRANSGENIC MOUSE; TUMOR MICROENVIRONMENT; ANIMAL; BRAIN TUMOR; C57BL MOUSE; CYTOTOXICITY TEST; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; GLIOMA; IMMUNOLOGY; IMMUNOTHERAPY; LYMPH NODE; METABOLISM; SURVIVAL RATE; T LYMPHOCYTE; TRANSPLANTATION; TUMOR ASSOCIATED LEUKOCYTE; VACCINATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLIOMA; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; INTERFERON-GAMMA; LYMPH NODES; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 77954634714     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop024     Document Type: Article

References (47)

1. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev. 2007;220:129-150.
2. Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213(1):131-145. (Pubitemid 44401498)
3. Gomez GG, Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol. 2006;10(a):133-146.
4. de Vleeschouwer S, Rapp M, Sorg RV, et al. Dendritic cell vaccination in patients with malignant gliomas: current status and future directions. Neurosurgery. 2006;59(5):988-999; discussion 999-1000.
5. Hussain SF, Heimberger AB. Immunotherapy for human glioma: innovative approaches and recent results. Expert Rev Anticancer Ther. 2005;5(5):777-790.
6. Platten M, Wick W, Weller M. Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech. 2001;52(4):401-410.
7. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-fbetag1 maintains suppressor function and Foxp3 expression in CD4 + CD25+ regulatory T cells. J Exp Med. 2005;201(7):1061-1067.
8. Wang HY, Wang R-F. Regulatory T cells and cancer. Curr Opin Immunol. 2007;19(2):217.
9. Grauer OM, Nierkens S, Bennink E, et al. CD4 + FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer. 2007;121(1):95-105.
10. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer. 2000;89(12):2646-2654.
11. Kikuchi T, Akasaki Y, Abe T, Ohno T. Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol Immunother. 2002;51(8):424-430.
12. Ehtesham M, Kabos P, Gutierrez MA, Samoto K, Black KL, Yu JS. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J Immunother 2003;26(2):107-116.
13. Teitz-Tennenbaum S, Li Q, Rynkiewicz S, et al. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res. 2003;63(23):8466-8475.
14. Yamanaka R, Tsuchiya N, Yajima N, et al. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J Neurosurg. 2003;99(4):746-753.
15. Kuwashima N, Nishimura F, Eguchi J, et al. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol. 2005;175(4):2730-2740.
16. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005;11(11):4160-4167.
17. Hu J, Yuan X, Belladonna ML, et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res. 2006;66(17):8887-8896.
18. Szatmari T, Lumniczky K, Desaknai S, et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 2006;97(6):546-553.
19. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med. 1997;186(7):1177-1182.
20. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4 + CD25+ T cell-mediated suppression by dendritic cells. Science. 2003;299(5609):1033-1036.
21. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005;65(8):3437-3446.
22. Chatzidakis I, Fousteri G, Tsoukatou D, Kollias G, Mamalaki C. An essential role for TNF in modulating thresholds for survival, activation, and tolerance of CD8+ T cells. J Immunol. 2007;178(11):6735-6745.
23. Villeneuve J, Tremblay P, Vallieres L. Tumor necrosis factor reduces brain tumor growth by enhancing macrophage recruitment and microcyst formation. Cancer Res. 2005;65(9):3928-3936.
24. Rescigno M, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta. 2007;1776(1):108-123.
25. Liao YP, Schaue D, McBride WH. Modification of the tumor microenvironment to enhance immunity. Front Biosci. 2007;12:3576-3600.
26. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 1996;93(7):2909-2914.
27. Fakhrai H, Mantil JC, Liu L, et al. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther. 2006;13(12):1052-1060.
28. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol. 2006;24:209-226.
29. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22(3):329-341.
30. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4 + CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330-336.
31. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4 + CD25+ T regulatory cells. Nat Immunol. 2003;4(4):337-342.
32. Pellegatta S, Poliani PL, Corno D, et al. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res. 2006;66(21): 10247-10252.
33. Tsugawa T, Kuwashima N, Sato H, et al. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response. Gene Ther. 2004;11(21):1551-1558.
34. Karman J, Ling C, Sandor M, Fabry Z. Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol. 2004;173(4): 2353-2361.
35. Hatterer E, Davoust N, Didier-Bazes M, et al. How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood. 2006;107(2): 806-812.
36. Fischer H-G, Reichmann G. Brain dendritic cells and macrophages/ microglia in central nervous system inflammation. J Immunol. 2001;166(4):2717-2726.
37. Karman J, Chu HH, Co DO, Seroogy CM, Sandor M, Fabry Z. Dendritic cells amplify T cell-mediated immune responses in the central nervous system. J Immunol. 2006;177(11):7750-7760.
38. Suter T, Biollaz G, Gatto D, et al. The brain as an immune privileged site: dendritic cells of the central nervous system inhibit T cell activation. Eur J Immunol. 2003;33(11):2998-3006.
39. Tanaka K, Ito A, Kobayashi T, et al. Intratumoral injection of immature dendritic cells enhances antitumor effect of hyperthermia using magnetic nanoparticles. Int J Cancer. 2005;116(4):624-633.
40. Guo J, Zhu J, Sheng X, et al. Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Int J Cancer. 2007;120(11): 2418-2425.
41. Mukhopadhaya A, Mendecki J, Dong X, et al. Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity. Cancer Res. 2007;67(16):7798-7806.
42. Saji H, Song W, Furumoto K, Kato H, Engleman EG. Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin Cancer Res. 2006;12(8):2568-2574.
43. Ladanyi A, Kiss J, Somlai B, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother. 2007;56(9):1459-1469.
44. Yoshida H, Imaizumi T, Fujimoto K, et al. Synergistic stimulation, by tumor necrosis factor-alpha and interferon-gamma, of fractalkine expression in human astrocytes. Neurosci Lett. 2001;303(2):132-136.
45. Xin H, Kikuchi T, Andarini S, et al. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells. Eur J Immunol. 2005;35(5):1371-1380.
46. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood. 2005;106(7):2252-2258.
47. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515-5525.